Litigation Details for ASTRAZENECA AB v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

ASTRAZENECA AB v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Docket		Date Filed	2014-12-17
Court	District Court, D. New Jersey	Date Terminated	2016-10-14
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	6,369,085; 7,411,070
Link to Docket	External link to docket

Details for ASTRAZENECA AB v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-17				External link to document

Litigation Summary and Analysis: AstraZeneca AB v. Actavis Laboratories FL, Inc. (D.N.J. Case No. 3:14-cv-07870)

Last updated: June 12, 2026

No substantive case-specific litigation record content (claims asserted, asserted patents and Orange Book ties, FDA/NDA/ANDA details, procedural posture, claim construction, final judgment, settlement terms, or injunction/launch outcomes) was provided for AstraZeneca AB v. Actavis Laboratories FL, Inc., 3:14-cv-07870. Without those inputs, a complete and accurate litigation summary cannot be produced.

What patents were asserted in AstraZeneca AB v. Actavis Laboratories FL, Inc. (3:14-cv-07870)?

What Paragraph IV ANDA challenge triggered the AstraZeneca v. Actavis case?

What was the court’s procedural posture in 3:14-cv-07870 (motions, stays, Markman)?

Did the case end in settlement, dismissal, or final judgment?

What did the settlement require (launch dates, payment, stipulations, injunction terms)?

How did claim scope and construction affect infringement and validity arguments?

What generic entry risks existed for Actavis if the case settled or was dismissed?

What is the Orange Book status for the AstraZeneca product involved in 3:14-cv-07870?

What companies competed with Actavis in the same ANDA/patent cluster?

How does this dispute compare with other AstraZeneca AB patent litigations vs generics?

Key Takeaways

FAQs

1. What does case number 3:14-cv-07870 typically correspond to in Hatch-Waxman litigation?
2. How do courts in the District of New Jersey usually handle stays under 35 U.S.C. § 271(e)(4) in ANDA patent cases?
3. What indicators in dockets signal settlement versus adjudication in AstraZeneca AB v. Actavis-type cases?
4. How should a patent estate’s expiration schedule be mapped to ANDA readiness for generic launch planning?
5. What Orange Book listing patterns predict higher probability of launch-delay settlements?

References